Drug Profile
Research programme: cannabinoid receptor CB1 antagonists - Bayer
Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Bayer
- Class Pyridones
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 21 Mar 2002 Preclinical trials in Obesity in Germany (unspecified route)